Many States Ignore Prevention in Plans to Spend Tobacco Funds

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 6
Volume 8
Issue 6

WASHINGTON-In at least one-third of the states, legislators have proposed spending less than 2% of the funds the state will receive from last year’s tobacco settlement on antitobacco prevention programs, according to a new report by the Campaign for Tobacco-Free Kids and the American Heart Association (AHA). The AHA says many state legislators are ignoring evidence that tobacco prevention programs work, especially those aimed at young people.

WASHINGTON—In at least one-third of the states, legislators have proposed spending less than 2% of the funds the state will receive from last year’s tobacco settlement on antitobacco prevention programs, according to a new report by the Campaign for Tobacco-Free Kids and the American Heart Association (AHA). The AHA says many state legislators are ignoring evidence that tobacco prevention programs work, especially those aimed at young people.

Four states have made a commitment to fund tobacco prevention programs beyond a minimal level, and eight others are considering such proposals. But in one-third of the states and the District of Columbia, allocating of funds was dominated by proposals for things totally unrelated to the purposes for which the states brought their lawsuits, such as reducing the car tax in Rhode Island and funding college scholarships in Michigan.

Recent Videos
2 KOLs are featured in this series
2 KOLs are featured in this series
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
Experts from Vanderbilt University Medical Center emphasize gathering a second opinion to determine if a tumor is resectable in patients with pancreatic cancer.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Experts from Vanderbilt University Medical Center discuss the use of intraoperative radiation therapy in a 64-year-old patient with pancreatic cancer.
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Related Content